Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA-STAR: STAR-0215 in Hereditary Angioedema
2022-502953-32-01Phase 2Completed
- Sponsor
- Astria Therapeutics
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, single-arm trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Primary endpoints: Incidence of adverse events and Changes in vital signs, ECG findings, physical examination findings, and clinical laboratory evaluations. Started Oct 2023; status: completed.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2022-502953-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502953-32-01.